Login
$OFIX
$6.80 +$0.00 (0.0%) After hours

$OFIX 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net ...

05 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

LEWISVILLE, Texas — August 5, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2026, reflecting progress toward a more foc...

02 Jul 2026 8-K: Regulation FD Disclosure

On April 16, 2026, the U.S. Food and Drug Administration (“FDA”) issued a final order reclassifying non-invasive bone growth stimulators from Class III to Class II devices. Following that order, the Centers for Medicare & Medicaid Servic...

11 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan (as amended to date, the “Plan”) is hereby amended as follows:

21 May 2026 8-K: Regulation FD Disclosure

On April 16, 2026, the U.S. Food and Drug Administration issued a final order reclassifying non-invasive bone growth stimulators from Class III to Class II devices. In connection with that reclassification, the Centers for Medicare & Med...

05 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

LEWISVILLE, Texas — May 5, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following re...

09 Apr 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Company Reports Preliminary First Quarter 2026 Net Sales and Reaffirms 2026 Outlook

24 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

LEWISVILLE, Texas — February 24, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2025, provided full-ye...

04 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

LEWISVILLE, Texas — November 4, 2025 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net...

05 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

LEWISVILLE, Texas — August 5, 2025 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2025, and reaffirmed its full-year 2025 fin...

20 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2025, Orthofix Medical Inc. (the “Company”) held its 2025 annual meeting of shareholders (the “Annual Meeting”). The total number of common shares eligible to vote as of the record date, April 21, 2025, was 39,180,306 and, pu...

06 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

LEWISVILLE, Texas — May 6, 2025 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales gui...

07 Apr 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

On April 1, 2025, Orthofix Medical Inc. (the “Company”) became tenant under a new lease governing its Carlsbad, California office location (5770 Armada Drive) (the “New Lease”), which became effective on such date. The Company had previo...

12 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

LEWISVILLE, Texas — March 12, 2025 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025.

25 Feb 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies

08 Nov 2024 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of November 7, 2024 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liabil...

07 Nov 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Building on Positive Momentum from Compelling Combination of Profitable, Above-Market Growth with a Stronger Financial Profile

06 Aug 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

LEWISVILLE, Texas — August 6, 2024 — Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance.

20 Jun 2024 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan (as amended to date, the “Plan”) is hereby amended as follows:

07 May 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Net sales of $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis over prior year

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support